Vista Pharmaceuticals reported a net loss of ₹98.59 Lakhs for the quarter ended June 30, 2026. The company continues to face financial challenges, including negative working capital and a decreasing net worth due to accumulated operational losses. These factors indicate a material uncertainty that casts doubt on its ability to continue as a going concern, although management is actively pursuing debt restructuring and cost-saving measures.
Vista Pharmaceuticals Reports Q1 2026 Financials
Vista Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a net loss of ₹98.59 Lakhs for the period. This figure represents a continuation of the financial difficulties the company has been experiencing, with the latest loss marking the sixth consecutive year of financial deficit.
Financial Health Concerns
The financial statements reveal significant concerns regarding the company’s operational stability. Vista Pharmaceuticals is facing a situation of negative working capital, with current liabilities exceeding current assets by ₹183.32 Lakhs as of June 30, 2026. Furthermore, the company’s net worth has been on a declining trend due to accumulated operational losses. These conditions have led to a classification of certain accounts as Non-Performing Assets (NPAs) by lender banks due to defaults in loan repayments.
Going Concern Uncertainty
These events and financial conditions collectively indicate a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern. The company’s credit facilities were also classified as a Non-Performing Asset (NPA) by a lender due to defaults in debt servicing, leading to a freeze on working capital accounts and temporarily constraining operational liquidity.
Management’s Mitigation Efforts
Despite these challenges, the interim financial results have been prepared on a ‘Going Concern’ basis. Management is actively engaged in negotiations for debt restructuring with lenders and is implementing aggressive cost-rationalisation measures. Additionally, the company has secured a formal financial undertaking from the subscribers of convertible share warrants to pay the call money amounting to ₹922.49 Lakhs, which is expected to help meet operational obligations. Consequently, no adjustments have been made to the carrying value or classification of assets and liabilities.
Source: BSE
